FR2967581B1 - Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques - Google Patents
Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriquesInfo
- Publication number
- FR2967581B1 FR2967581B1 FR1059561A FR1059561A FR2967581B1 FR 2967581 B1 FR2967581 B1 FR 2967581B1 FR 1059561 A FR1059561 A FR 1059561A FR 1059561 A FR1059561 A FR 1059561A FR 2967581 B1 FR2967581 B1 FR 2967581B1
- Authority
- FR
- France
- Prior art keywords
- polymeric
- preparation
- active ingredients
- intermediates
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1059561A FR2967581B1 (fr) | 2010-11-19 | 2010-11-19 | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
UY0001033741A UY33741A (es) | 2010-11-19 | 2011-11-18 | Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos |
ARP110104306A AR084728A1 (es) | 2010-11-19 | 2011-11-18 | Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos |
HUE11784668A HUE032590T2 (en) | 2010-11-19 | 2011-11-18 | Polymer conjugates of active substances, processes for their preparation, and intermediates of polymers |
PT117846683T PT2640422T (pt) | 2010-11-19 | 2011-11-18 | Conjugados poliméricos de princípios ativos, seu processo de preparação e seus intermediários poliméricos |
EP11784668.3A EP2640422B1 (fr) | 2010-11-19 | 2011-11-18 | Conjugués polymères de principes actifs, leur procédé de préparation et leurs intermédiaires polymères |
RS20170450A RS56021B1 (sr) | 2010-11-19 | 2011-11-18 | Polimerni konjugati aktivnih principa, procesi za njihovu pripremu i njihovi polimerni interminedijari |
TW100142380A TW201302225A (zh) | 2010-11-19 | 2011-11-18 | 活性成份之聚合共軛物,其製備方法及其聚合中間物 |
SI201131184T SI2640422T1 (sl) | 2010-11-19 | 2011-11-18 | Polimerni konjugati aktivnih učinkovin, postopek njihove priprave in njihove polimerne vmesne spojine |
PL11784668T PL2640422T3 (pl) | 2010-11-19 | 2011-11-18 | Polimerowe koniugaty aktywnych zasad, sposób ich otrzymywania i ich polimerowe produkty pośrednie |
PCT/EP2011/070441 WO2012066117A1 (fr) | 2010-11-19 | 2011-11-18 | Conjugués polymères de principes actifs, leur procédé de préparation et leurs intermédiaires polymères |
DK11784668.3T DK2640422T3 (en) | 2010-11-19 | 2011-11-18 | POLYMER CONJUGATES OF ACTIVE INGREDIENTS, METHOD OF MANUFACTURING THEREOF AND THEIR POLYMER INTERMEDIATES |
LTEP11784668.3T LT2640422T (lt) | 2010-11-19 | 2011-11-18 | Veikliųjų medžiagų polimeriniai konjugatai, jų gamybos būdas ir jų polimeriniai tarpiniai junginiai |
ES11784668.3T ES2625173T3 (es) | 2010-11-19 | 2011-11-18 | Conjugados poliméricos de principios activos, su procedimiento de preparación y sus intermedios poliméricos |
JP2013539283A JP6013354B2 (ja) | 2010-11-19 | 2011-11-18 | 活性成分のポリマーコンジュゲート、その製造方法及びそのポリマー中間体 |
US13/877,757 US9278137B2 (en) | 2010-11-19 | 2011-11-18 | Polymeric conjugates of active principles, their process of preparation and their polymeric intermediates |
JP2016080318A JP6165920B2 (ja) | 2010-11-19 | 2016-04-13 | 活性成分のポリマーコンジュゲート、その製造方法及びそのポリマー中間体 |
HRP20170691TT HRP20170691T1 (hr) | 2010-11-19 | 2017-05-10 | Polimerni konjugati djelatnih tvari, njihov postupak dobivanja i njihovi polimerni intermedijeri |
CY20171100570T CY1119115T1 (el) | 2010-11-19 | 2017-05-31 | Πολυμερικα συζευγματα δραστικων αρχων, η διαδικασια παρασκευης τους και οι πολυμερικες ενδιαμεσες ενωσεις τους |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1059561A FR2967581B1 (fr) | 2010-11-19 | 2010-11-19 | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2967581A1 FR2967581A1 (fr) | 2012-05-25 |
FR2967581B1 true FR2967581B1 (fr) | 2012-12-28 |
Family
ID=43654132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1059561A Active FR2967581B1 (fr) | 2010-11-19 | 2010-11-19 | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
Country Status (18)
Country | Link |
---|---|
US (1) | US9278137B2 (fr) |
EP (1) | EP2640422B1 (fr) |
JP (2) | JP6013354B2 (fr) |
AR (1) | AR084728A1 (fr) |
CY (1) | CY1119115T1 (fr) |
DK (1) | DK2640422T3 (fr) |
ES (1) | ES2625173T3 (fr) |
FR (1) | FR2967581B1 (fr) |
HR (1) | HRP20170691T1 (fr) |
HU (1) | HUE032590T2 (fr) |
LT (1) | LT2640422T (fr) |
PL (1) | PL2640422T3 (fr) |
PT (1) | PT2640422T (fr) |
RS (1) | RS56021B1 (fr) |
SI (1) | SI2640422T1 (fr) |
TW (1) | TW201302225A (fr) |
UY (1) | UY33741A (fr) |
WO (1) | WO2012066117A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014015422A1 (fr) * | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Nanoparticules à base de cellulose pour administration de médicament |
SG11201504235UA (en) * | 2012-12-28 | 2015-07-30 | Blend Therapeutics Inc | Targeted conjugates encapsulated in particles and formulations thereof |
JP6543258B2 (ja) | 2013-09-16 | 2019-07-10 | アストラゼネカ アクチボラグ | 治療用重合性ナノ粒子とそれを作製して使用する方法 |
WO2017147240A1 (fr) | 2016-02-23 | 2017-08-31 | Tarveda Therapeutics, Inc. | Conjugués et particules ciblant hsp90 et leurs formulations |
KR20210034011A (ko) * | 2018-07-19 | 2021-03-29 | 스타파마 피티와이 리미티드 | 치료 덴드리머 |
CN110974972B (zh) * | 2019-12-03 | 2023-01-20 | 沈阳药科大学 | 难溶性药物的弱酸性衍生物及其脂质体制剂 |
CN113933441A (zh) * | 2021-09-30 | 2022-01-14 | 无锡紫杉药业有限公司 | 一种卡巴他赛及其中间体的测定方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
CZ2006207A3 (cs) * | 2006-03-28 | 2008-01-16 | Zentiva, A. S. | Micelární nosiče léčiv s protinádorovou aktivitou |
CN101701068B (zh) * | 2009-10-30 | 2011-09-21 | 北京化工大学 | 一种pH响应性的Y型药物输送材料及其制备方法 |
WO2011119995A2 (fr) * | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations et procédés d'utilisation |
CN103408710B (zh) * | 2013-06-19 | 2015-12-23 | 北京化工大学 | 一种生物可降解及糖响应性的y型高分子药物输送材料及制备 |
-
2010
- 2010-11-19 FR FR1059561A patent/FR2967581B1/fr active Active
-
2011
- 2011-11-18 SI SI201131184T patent/SI2640422T1/sl unknown
- 2011-11-18 DK DK11784668.3T patent/DK2640422T3/en active
- 2011-11-18 TW TW100142380A patent/TW201302225A/zh unknown
- 2011-11-18 ES ES11784668.3T patent/ES2625173T3/es active Active
- 2011-11-18 RS RS20170450A patent/RS56021B1/sr unknown
- 2011-11-18 PL PL11784668T patent/PL2640422T3/pl unknown
- 2011-11-18 US US13/877,757 patent/US9278137B2/en active Active
- 2011-11-18 PT PT117846683T patent/PT2640422T/pt unknown
- 2011-11-18 JP JP2013539283A patent/JP6013354B2/ja active Active
- 2011-11-18 EP EP11784668.3A patent/EP2640422B1/fr active Active
- 2011-11-18 HU HUE11784668A patent/HUE032590T2/en unknown
- 2011-11-18 UY UY0001033741A patent/UY33741A/es not_active Application Discontinuation
- 2011-11-18 LT LTEP11784668.3T patent/LT2640422T/lt unknown
- 2011-11-18 AR ARP110104306A patent/AR084728A1/es not_active Application Discontinuation
- 2011-11-18 WO PCT/EP2011/070441 patent/WO2012066117A1/fr active Application Filing
-
2016
- 2016-04-13 JP JP2016080318A patent/JP6165920B2/ja active Active
-
2017
- 2017-05-10 HR HRP20170691TT patent/HRP20170691T1/hr unknown
- 2017-05-31 CY CY20171100570T patent/CY1119115T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT2640422T (pt) | 2017-05-23 |
FR2967581A1 (fr) | 2012-05-25 |
TW201302225A (zh) | 2013-01-16 |
HRP20170691T1 (hr) | 2018-05-18 |
JP6013354B2 (ja) | 2016-10-25 |
US9278137B2 (en) | 2016-03-08 |
JP2016172858A (ja) | 2016-09-29 |
SI2640422T1 (sl) | 2017-10-30 |
PL2640422T3 (pl) | 2017-09-29 |
LT2640422T (lt) | 2017-06-26 |
US20130243719A1 (en) | 2013-09-19 |
WO2012066117A1 (fr) | 2012-05-24 |
EP2640422A1 (fr) | 2013-09-25 |
CY1119115T1 (el) | 2018-02-14 |
AR084728A1 (es) | 2013-06-05 |
HUE032590T2 (en) | 2017-10-30 |
RS56021B1 (sr) | 2017-09-29 |
UY33741A (es) | 2012-03-30 |
ES2625173T3 (es) | 2017-07-18 |
JP6165920B2 (ja) | 2017-07-19 |
JP2013542972A (ja) | 2013-11-28 |
EP2640422B1 (fr) | 2017-03-01 |
DK2640422T3 (en) | 2017-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR19C1040I2 (fr) | Administration par voie respiratoire de principes actifs | |
CO6811868A2 (es) | Combinaciones de principios activos | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
BR112013030472A2 (pt) | formulação farmacêutica, artigo de fabricação e método | |
FR2986002B1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
BR112013033811A2 (pt) | composição, método de preparação da composição, e, composto | |
FR2967581B1 (fr) | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques | |
FR2963007B1 (fr) | Derives anticancereux, leur preparation et leur application therapeutique | |
BR112014004192A2 (pt) | composição de tratamento de sementes, e, método de tratamento de sementes | |
FR2974576B1 (fr) | Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique | |
BR112012023355A2 (pt) | composto, composição farmacêutica e método de ruptura da interação nek2/hec1 | |
FR2953520B1 (fr) | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique | |
FR2946888B1 (fr) | Procede de preparation de nacre mecanostructuree par mecano-synthese, nacre mecanostructuree ainsi obtenue et ses applications | |
FR2949465B1 (fr) | Derives chromones, leur procede de preparation et leurs applications therapeutiques | |
FR2952934B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
EP2777713A4 (fr) | Conjugué médicamenteux de polyéthylèneglycol-oligopeptide d'acides aminés-irinotécan et composition médicamenteuse de celui-ci | |
BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
BR112013017267A2 (pt) | formulação de lipossomas, suspensão e composição farmacêutica | |
FR2966150B1 (fr) | Procede de preparation de la 2-hydroxybutyrolactone | |
FR2973037B1 (fr) | Adhesifs structuraux, procede pour leur preparation, et leur application | |
SMT201600243B (it) | Composizioni farmaceutiche comprendenti anakinra senza citrato | |
FR2934962B1 (fr) | Catalyseurs zeolithiques, leur procede de preparation et leurs applications | |
FR2967672B1 (fr) | Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques | |
BR112013033052A2 (pt) | formulações de entrega de fármaco | |
BR112013010541A2 (pt) | método de preparação de 1,3,5-trioxano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CA | Change of address |
Effective date: 20120620 |
|
CD | Change of name or company name |
Owner name: UNIVERSITE PAUL SABATIER TOULOUSE III, FR Effective date: 20120620 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR Effective date: 20120620 Owner name: SANOFI, FR Effective date: 20120620 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |